Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas 77030, USA.
Arch Pathol Lab Med. 2013 Feb;137(2):241-4. doi: 10.5858/arpa.2012-0176-OA. Epub 2012 Sep 14.
Lung cancer is the number one cause of cancer deaths in the United States and globally. The advent of targeted therapies has offered a new treatment paradigm for lung cancer, but currently validated and emerging drugs are effective in only a small minority of lung cancers, predominantly adenocarcinomas. Folate receptors can serve as targets for drugs attached to folate and are overexpressed in many cancers.
To determine the frequency of folate receptor overexpression in lung cancers of different cell types as potential targets for folate-linked therapy.
High-density tissue microarrays were constructed from archival formalin-fixed, paraffin-embedded resection specimens from 188 primary stage I or stage II adenocarcinomas or squamous cell carcinomas of the lung with three 0.1-cm cores from each tumor. Tissue microarrays were immunostained for folate receptor α with mAb343 and the results scored (0 to 1+ = weak expression, 2+ to 3+ = strong expression).
Eighty-four of 117 (72%) of the adenocarcinomas were strongly positive for the folate receptor, and 36 of 71 (51%) of the squamous cell carcinomas were strongly positive for the folate receptor.
Our data indicate that a large percentage of lung cancers, including squamous cell carcinomas in addition to adenocarcinomas, strongly express folate receptor. This suggests that folate-linked targeted therapy can potentially be used to treat the majority of lung cancers, both adenocarcinomas and, particularly, squamous cell carcinomas, that do not respond to current targeted therapies.
肺癌是美国和全球癌症死亡的首要原因。靶向治疗的出现为肺癌治疗提供了新的范例，但目前经过验证和新兴的药物仅对一小部分肺癌有效，主要是腺癌。叶酸受体可以作为与叶酸结合的药物的靶点，在许多癌症中过度表达。
确定不同细胞类型肺癌中叶酸受体过表达的频率，作为叶酸相关治疗的潜在靶点。
从 188 例原发性 I 期或 II 期腺癌或肺鳞癌的存档福尔马林固定、石蜡包埋的切除标本中构建高密度组织微阵列，每个肿瘤有 3 个 0.1cm 的核心。用 mAb343 对组织微阵列进行叶酸受体α免疫染色，并对结果进行评分（0 到 1+ = 弱阳性，2+ 到 3+ = 强阳性）。
117 例腺癌中有 84 例（72%）强烈表达叶酸受体，71 例鳞癌中有 36 例（51%）强烈表达叶酸受体。
我们的数据表明，很大一部分肺癌，包括除腺癌以外的鳞癌，强烈表达叶酸受体。这表明叶酸结合的靶向治疗可能可用于治疗大多数肺癌，包括腺癌，尤其是对目前靶向治疗无反应的鳞癌。
Zotero 插件